Researchers at ASH shared Phase III data comparing the pre- and five-year post-treatment adjusted annualized bleeding rates, ...

The firm said it is planning a regulatory filing with the European Medicines Agency next year to begin clinical studies of PCT1:CO-STIM.

As part of the trial, investigators will initially evaluate ARO-MAPT in up to 64 healthy subjects, followed by up to 48 Alzheimer's disease patients.

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.

At the meeting, researchers shared real-world data showing ctDNA positivity at the end of treatment was prognostic across lymphoma subtypes and better than PET scans.

In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...